Comparison between Colistin Sulfate Dry Powder and Solution for Pulmonary Delivery

To assess the difference in the fate of the antibiotic colistin (COLI) after its pulmonary delivery as a powder or a solution, we developed a COLI powder and evaluated the COLI pharmacokinetic properties in rats after pulmonary administration of the powder or the solution. The amorphous COLI powder...

Full description

Bibliographic Details
Main Authors: Frédéric Tewes, Julien Brillault, Nicolas Gregoire, Jean-Christophe Olivier, Isabelle Lamarche, Christophe Adier, Anne-Marie Healy, Sandrine Marchand
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Pharmaceutics
Subjects:
Online Access:https://www.mdpi.com/1999-4923/12/6/557
id doaj-1117420f113041e1856723077907d212
record_format Article
spelling doaj-1117420f113041e1856723077907d2122020-11-25T03:20:57ZengMDPI AGPharmaceutics1999-49232020-06-011255755710.3390/pharmaceutics12060557Comparison between Colistin Sulfate Dry Powder and Solution for Pulmonary DeliveryFrédéric Tewes0Julien Brillault1Nicolas Gregoire2Jean-Christophe Olivier3Isabelle Lamarche4Christophe Adier5Anne-Marie Healy6Sandrine Marchand7INSERM U1070 “Pharmacology of anti-infective agents”, 1 rue Georges Bonnet, Pôle Biologie Santé, 86022 Poitiers Cedex, FranceINSERM U1070 “Pharmacology of anti-infective agents”, 1 rue Georges Bonnet, Pôle Biologie Santé, 86022 Poitiers Cedex, FranceINSERM U1070 “Pharmacology of anti-infective agents”, 1 rue Georges Bonnet, Pôle Biologie Santé, 86022 Poitiers Cedex, FranceUFR Médecine-Pharmacie Université de Poitiers, 6 rue de la milétrie, TSA 51115, 86073 Poitiers Cedex 9, FranceINSERM U1070 “Pharmacology of anti-infective agents”, 1 rue Georges Bonnet, Pôle Biologie Santé, 86022 Poitiers Cedex, FranceINSERM U1070 “Pharmacology of anti-infective agents”, 1 rue Georges Bonnet, Pôle Biologie Santé, 86022 Poitiers Cedex, FranceSSPC, The Science Foundation Ireland Research Centre for Pharmaceuticals, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Panoz Institute, D02 PN40 Dublin 2, IrelandINSERM U1070 “Pharmacology of anti-infective agents”, 1 rue Georges Bonnet, Pôle Biologie Santé, 86022 Poitiers Cedex, FranceTo assess the difference in the fate of the antibiotic colistin (COLI) after its pulmonary delivery as a powder or a solution, we developed a COLI powder and evaluated the COLI pharmacokinetic properties in rats after pulmonary administration of the powder or the solution. The amorphous COLI powder prepared by spray drying was characterized by a mass median aerodynamic diameter and fine particle fraction of 2.68 ± 0.07 µm and 59.5 ± 5.4%, respectively, when emitted from a Handihaler<sup>®</sup>. After intratracheal administration, the average pulmonary epithelial lining fluid (ELF): plasma area under the concentration versus time curves (AUC) ratios were 570 and 95 for the COLI solution and powder, respectively. However, the same COLI plasma concentration profiles were obtained with the two formulations. According to our pharmacokinetic model, this difference in ELF COLI concentration could be due to faster systemic absorption of COLI after the powder inhalation than for the solution. In addition, the COLI apparent permeability (P<sub>app</sub>) across a Calu-3 epithelium model increased 10-fold when its concentration changed from 100 to 4000 mg/L. Based on this last result, we propose that the difference observed in vivo between the COLI solution and powder could be due to a high local ELF COLI concentration being obtained at the site where the dry particles impact the lung. This high local COLI concentration can lead to a local increase in COLI P<sub>app</sub>, which is associated with a high concentration gradient and could produce a high local transfer of COLI across the epithelium and a consequent increase in the overall absorption rate of COLI.https://www.mdpi.com/1999-4923/12/6/557colistin dry powder inhalationpulmonary infectionsnebulizationpharmacokinetics modelingCalu-3 permeability
collection DOAJ
language English
format Article
sources DOAJ
author Frédéric Tewes
Julien Brillault
Nicolas Gregoire
Jean-Christophe Olivier
Isabelle Lamarche
Christophe Adier
Anne-Marie Healy
Sandrine Marchand
spellingShingle Frédéric Tewes
Julien Brillault
Nicolas Gregoire
Jean-Christophe Olivier
Isabelle Lamarche
Christophe Adier
Anne-Marie Healy
Sandrine Marchand
Comparison between Colistin Sulfate Dry Powder and Solution for Pulmonary Delivery
Pharmaceutics
colistin dry powder inhalation
pulmonary infections
nebulization
pharmacokinetics modeling
Calu-3 permeability
author_facet Frédéric Tewes
Julien Brillault
Nicolas Gregoire
Jean-Christophe Olivier
Isabelle Lamarche
Christophe Adier
Anne-Marie Healy
Sandrine Marchand
author_sort Frédéric Tewes
title Comparison between Colistin Sulfate Dry Powder and Solution for Pulmonary Delivery
title_short Comparison between Colistin Sulfate Dry Powder and Solution for Pulmonary Delivery
title_full Comparison between Colistin Sulfate Dry Powder and Solution for Pulmonary Delivery
title_fullStr Comparison between Colistin Sulfate Dry Powder and Solution for Pulmonary Delivery
title_full_unstemmed Comparison between Colistin Sulfate Dry Powder and Solution for Pulmonary Delivery
title_sort comparison between colistin sulfate dry powder and solution for pulmonary delivery
publisher MDPI AG
series Pharmaceutics
issn 1999-4923
publishDate 2020-06-01
description To assess the difference in the fate of the antibiotic colistin (COLI) after its pulmonary delivery as a powder or a solution, we developed a COLI powder and evaluated the COLI pharmacokinetic properties in rats after pulmonary administration of the powder or the solution. The amorphous COLI powder prepared by spray drying was characterized by a mass median aerodynamic diameter and fine particle fraction of 2.68 ± 0.07 µm and 59.5 ± 5.4%, respectively, when emitted from a Handihaler<sup>®</sup>. After intratracheal administration, the average pulmonary epithelial lining fluid (ELF): plasma area under the concentration versus time curves (AUC) ratios were 570 and 95 for the COLI solution and powder, respectively. However, the same COLI plasma concentration profiles were obtained with the two formulations. According to our pharmacokinetic model, this difference in ELF COLI concentration could be due to faster systemic absorption of COLI after the powder inhalation than for the solution. In addition, the COLI apparent permeability (P<sub>app</sub>) across a Calu-3 epithelium model increased 10-fold when its concentration changed from 100 to 4000 mg/L. Based on this last result, we propose that the difference observed in vivo between the COLI solution and powder could be due to a high local ELF COLI concentration being obtained at the site where the dry particles impact the lung. This high local COLI concentration can lead to a local increase in COLI P<sub>app</sub>, which is associated with a high concentration gradient and could produce a high local transfer of COLI across the epithelium and a consequent increase in the overall absorption rate of COLI.
topic colistin dry powder inhalation
pulmonary infections
nebulization
pharmacokinetics modeling
Calu-3 permeability
url https://www.mdpi.com/1999-4923/12/6/557
work_keys_str_mv AT frederictewes comparisonbetweencolistinsulfatedrypowderandsolutionforpulmonarydelivery
AT julienbrillault comparisonbetweencolistinsulfatedrypowderandsolutionforpulmonarydelivery
AT nicolasgregoire comparisonbetweencolistinsulfatedrypowderandsolutionforpulmonarydelivery
AT jeanchristopheolivier comparisonbetweencolistinsulfatedrypowderandsolutionforpulmonarydelivery
AT isabellelamarche comparisonbetweencolistinsulfatedrypowderandsolutionforpulmonarydelivery
AT christopheadier comparisonbetweencolistinsulfatedrypowderandsolutionforpulmonarydelivery
AT annemariehealy comparisonbetweencolistinsulfatedrypowderandsolutionforpulmonarydelivery
AT sandrinemarchand comparisonbetweencolistinsulfatedrypowderandsolutionforpulmonarydelivery
_version_ 1724615579112833024